A Retrospective Study Assessing clinical outcomes and safety of (nivolumab, carboplatin + paclitaxel, pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology